6505--Venlafaxine 24HR Sustained Action Capsules

The Department of Veterans Affairs National Acquisition Center is soliciting offers for Venlafaxine Hydrochloride 24-Hour Sustained Action Capsules in multiple dosage strengths (37.5 mg, 75 mg, and 150 mg) and package sizes (30, 90, 500, and 1,000 capsules per bottle). This is an Indefinite-Delivery Requirements contract using Firm Fixed Pricing with a single award covering nine line items across the federal health system. Key contract requirements include maintaining FDA cGMP acceptable status at all manufacturing facilities, submitting product registration to the FDA and multiple pharmaceutical databases within five calendar days of award, and establishing business-to-business agreements with designated Prime Vendor programs (McKesson for VA; McKesson, Cencora, Cardinal Health, and DMS Pharmaceutical Group for DoD). Offerors who are not manufacturers must provide a Letter of Commitment from the manufacturer, and all pricing must include a 0.5% Cost Recovery Fee. The offer due date is April 2, 2026, at 2:30 PM Central Daylight Time, with the Contracting Officer being Andrew Cazares (andrew.cazares@va.gov, 708-786-7990).

This is an unrestricted solicitation with no set-aside designation. The combined estimated annual usage is approximately 735,000 bottles across the Department of Veterans Affairs, Department of Defense, Indian Health Service, Bureau of Prisons, and other federal health entities, though specific dollar values are not disclosed in the solicitation materials. Offerors must provide pricing for the base year and all four one-year option periods, with an implementation period of up to 60 days allowed before the one-year ordering period begins. Non-small business concerns must submit an approved subcontracting plan with minimum goals for service-disabled veteran-owned and veteran-owned small business participation. The NAICS code is 325412 (Pharmaceutical Preparation Manufacturing) with a small business size standard of 1,300 employees, and distribution will occur through the identified Prime Vendor programs serving multiple federal health agencies.